Sona Nanotech signs Chile trial partner for targeted hyperthermia therapy trial - ICYMI

Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company’s latest step in advancing its targeted hyperthermia therapy (THT) towards market approval.

Speaking from a major biotech conference in Boston, Regan shared details on a newly signed clinical trial agreement in Chile.

The upcoming study will focus on late-stage melanoma patients who have not responded to leading immunotherapy treatments. Regan outlined that the study will involve ten patients receiving two applications of the THT therapy, followed by a 28-day monitoring period. The primary focus will be on safety and tolerability, though efficacy data will also be collected and reported.

Proactive: All right, welcome back inside our Proactive newsroom. And joining me now from Boston at one of the biggest biotech conferences you'll see is David Regan. He's the CEO of Sona Nanotech. And David, thanks for joining us from the conference. It's a busy one.

David Regan: My pleasure. Yeah, it is pretty crazy. It's got about 6,000 attendees at this conference. All the big pharma as well as the small biotechs are here coming to do partnering.

So that's the idea of this — to sort of meet people that potentially could invest within the company.

Yes, it's investors, collaborators, and partners. Everyone who's everyone is here. A great session. A lot of booths up here, a lot of biotech companies, and a lot of discussions we're having with potential partners.

Okay. We should talk about today's news. You’ve entered into a clinical trial agreement in Chile for a feasibility study of your therapy. Give us a quick overview of what this is about.

Sure. This is another key step in our progress in getting our targeted hyperthermia therapy approved into market. And of course, it's getting that clinical data, that important human data. We've just signed up a tremendous clinical partner in Santiago who has a lot of experience working with tier one operators like Merck and Regeneron, as is listed on their website. This is the key step. The next one will be getting ethics approval.

Yeah, and so this will just be sort of the beginning part of it. Right? This is sort of the safety part of it?

So it's a ten patient study. In any medical device early feasibility study, your focus is always on safety and tolerability. Of course, we're going to be looking for efficacy data too. And we're going to be very explicit in terms of sharing with folks exactly what that efficacy data is and what those metrics are that we're going to be looking for.

And just really quickly on timeline — I know you're expecting some interim results by the end of the summer and then more in the fall. Is that accurate?

Yeah, that's absolutely correct. We're expecting Ethics Committee approval shortly. We'll announce that. After that, that is the key thing to allow us to go and start recruiting patients and applying our therapy with these patients. These patients are going to be late-stage melanoma patients who have failed the best immunotherapy treatments in the world. We're going to use two applications of our THT therapy and track them for 28 days. We're looking for ten patients. We hope to have interim results middle of the summer and full results towards the end in the September to Fall. Very excited about it because this is the first time we're actually getting to show what it does in humans and how helpful it can be and what we expect for these patients.

Quotes have been lightly edited for clarity and style